{"id":5850,"date":"2024-10-31T16:10:24","date_gmt":"2024-10-31T21:10:24","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5850"},"modified":"2025-06-27T11:07:05","modified_gmt":"2025-06-27T16:07:05","slug":"nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bMCO-010\u306e2\u5e74\u9593\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u3092\u767a\u8868"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5850\" class=\"elementor elementor-5850\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-54ac0541 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"54ac0541\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-367865ba\" data-id=\"367865ba\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-45ffa5a0 elementor-widget elementor-widget-text-editor\" data-id=\"45ffa5a0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\u30c0\u30e9\u30b9\u30012024\u5e7410\u670831\u65e5 \u2014 \u7db2\u819c\u5909\u6027\u75be\u60a3\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3057\u3066\u3044\u308bBLA\u7533\u8acb\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bNanoscope Therapeutics, Inc.\u306f\u672c\u65e5\u3001\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u3088\u308b\u6c38\u4e45\u7684\u304b\u3064\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5909\u7570\u975e\u4f9d\u5b58\u578b\u907a\u4f1d\u5b50\u6cbb\u7642\u85ac\u3067\u3042\u308b\u4e3b\u529b\u30d7\u30ed\u30b0\u30e9\u30e0MCO-010\u306e\u7b2c2b\u76f8RESTORE\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u81e8\u5e8a\u8a66\u9a13\uff08RCT\uff09\u306e\u826f\u597d\u306a2\u5e74\u9593\u306e\u7d50\u679c\u304c\u3001\u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u306e\u7db2\u819c\u7814\u7a76\u90e8\u9577\u517c\u7db2\u819c\u79d1\u5171\u540c\u90e8\u9577\u3067\u3042\u308a\u3001Nanoscope\u306e\u6700\u9ad8\u533b\u7642\u9867\u554f\u3067\u3082\u3042\u308bAllen C. Ho\u533b\u5e2b\uff08MD\u3001FACS\u3001FASRS\uff09\u306b\u3088\u3063\u3066\u30012024\u5e7410\u670820\u65e5\u306b\u6700\u8fd1\u9589\u5e55\u3057\u305fAAO 2024\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002 \u300c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306b\u304a\u3051\u308b\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306eMCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\uff1a\u7b2c1\u76f8\u8a66\u9a13\u306e2\u5e74\u9593\u306e\u4e3b\u8981\u7d50\u679c\u300d\u3068\u984c\u3057\u305f\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u4e2d\u3067\u3001\u00a0<span class=\"xn-money\">2b<\/span>\u300c\u7121\u4f5c\u70ba\u5316\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08RESTORE\uff09\u300d\u306b\u304a\u3044\u3066\u3001\u30db\u30fc\u535a\u58eb\u306f\u3001\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13\u306e\u671f\u9593\u4e2d\u3001\u5f8c\u306e\u6642\u70b9\u306b\u304a\u3044\u3066\u3082\u7dad\u6301\u3055\u308c\u305f\u3001\u5e73\u5747\u7d040.3 LogMAR\uff083\u884c15\u6587\u5b57\u76f8\u5f53\uff09\u306e\u6700\u9ad8\u77ef\u6b63\u8996\u529b\uff08BCVA\uff09\u306e\u6539\u5584\u3068\u3044\u3046\u6e2c\u5b9a\u3055\u308c\u305f\u52b9\u679c\u3092\u5f37\u8abf\u3057\u305f\u3002\u305d\u306e\u4ed6\u306e\u6240\u898b\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3042\u308b\u3002\n<ul type=\"disc\">\n \t<li>\u9ad8\u7528\u91cfMCO-010\u7fa4\u3067\u306f\u300152\u9031\u76ee\uff08\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\uff09\u306876\u9031\u76ee\uff08\u4e3b\u8981\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\uff09\u3067\u305d\u308c\u305e\u308c0.337 \u00b1 0.0829\u30680.539 \u00b1 0.1032 LogMAR\uff08\u5bfe\u7167\u7fa4\u306b\u5bfe\u3057\u3066\u3001p = 0.0209\u30680.0014\uff09\u306e\u5e73\u5747\u6539\u5584\u304c\u898b\u3089\u308c\u3001\u4f4e\u7528\u91cfMCO-010\u7fa4\u3067\u306f\u3001\u540c\u3058\u6642\u70b9\u3067\u305d\u308c\u305e\u308c0.382 \u00b1 0.1244\u30680.374 \u00b1 0.1332 LogMAR\uff08\u5bfe\u7167\u7fa4\u306b\u5bfe\u3057\u3066\u3001p = 0.0290\u30680.0652\uff09\u306e\u5e73\u5747\u6539\u5584\u304c\u898b\u3089\u308c\u307e\u3057\u305f\uff08<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">\u4ee5\u524d\u306b\u767a\u8868\u3055\u308c\u305f<\/a>).<\/li>\n \t<li>52\u9031\u76ee\u306b\u3001MCO-010\u3092\u6295\u4e0e\u3055\u308c\u305f18\u4eba\u4e2d7\u4eba\uff0839%\uff09\u306fBCVA\u6539\u5584\u304c0.3 LogMAR\u4ee5\u4e0a\u3092\u793a\u3057\u300118\u4eba\u4e2d10\u4eba\uff0856%\uff09\u306f76\u9031\u76ee\u306b\u3053\u306e\u95be\u5024\u306b\u9054\u3057\u307e\u3057\u305f\u3002<\/li>\n \t<li>\u7e26\u65ad\u7684\u5206\u6790\u3067\u306f\u300136 \u9031\u76ee\u304b\u3089 88 \u9031\u76ee\u306e\u8a3a\u5bdf\u3067\u3001\u6a21\u64ec\u5bfe\u7167\u3068\u6bd4\u8f03\u3057\u3066\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u5e73\u5747 BCVA \u6539\u5584\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002<\/li>\n \t<li>52 \u9031\u76ee\u300176 \u9031\u76ee\u3001100 \u9031\u76ee\u307e\u3067\u306e BCVA \u66f2\u7dda\u4e0b\u9762\u7a4d\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001MCO-010 \u306e\u4e21\u6295\u4e0e\u7fa4\u3067\u6a21\u64ec\u5bfe\u7167\u7fa4\u3068\u6bd4\u8f03\u3057\u3066 5 \u500d\u5927\u304d\u304f\u3001\u7d71\u8a08\u7684\u306b\u6709\u610f\u3067\u3057\u305f\u3002<\/li>\n \t<li>MCO-010 \u306f\u5fcd\u5bb9\u6027\u304c\u826f\u597d\u3067\u3001MCO-010 \u30b0\u30eb\u30fc\u30d7\u3067\u306f\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002\u6700\u3082\u591a\u304f\u5831\u544a\u3055\u308c\u305f\u6709\u5bb3\u4e8b\u8c61\u306f\u3001\u524d\u623f\u7d30\u80de (44% MCO-010\u300122% \u6a21\u64ec\u5bfe\u7167) \u3068\u773c\u5727\u4ea2\u9032 (39% MCO-010\u300111% \u6a21\u64ec\u5bfe\u7167) \u3067\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u6709\u5bb3\u4e8b\u8c61\u306f\u3001\u5c40\u6240\u85ac\u3067\u89e3\u6d88\u307e\u305f\u306f\u6291\u5236\u3055\u308c\u307e\u3057\u305f\u3002<\/li>\n<\/ul>\n\u201c\u300c2\u5e74\u9593\u306e\u7814\u7a76\u671f\u9593\u4e2d\u306b\u8907\u6570\u306e\u6642\u70b9\u3067\u9054\u6210\u3055\u308c\u305f\u3001\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u6301\u7d9a\u7684\u306a\u8996\u529b\u6539\u5584\u306f\u975e\u5e38\u306b\u6ce8\u76ee\u306b\u5024\u3057\u307e\u3059\u3002\u3053\u306e\u7a0b\u5ea6\u306e\u6539\u5584\u306f\u3001\u975e\u5e38\u306b\u591a\u69d8\u306a\u91cd\u5ea6\u8996\u529b\u55aa\u5931\u60a3\u8005\u96c6\u56e3\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u306f\u3053\u308c\u307e\u3067\u89b3\u5bdf\u3055\u308c\u305f\u3053\u3068\u304c\u3042\u308a\u307e\u305b\u3093\u300d\u3068\u30db\u30fc\u535a\u58eb\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u60a3\u8005\u3068\u773c\u79d1\u533b\u306b\u89e3\u6c7a\u7b56\u304c\u9593\u3082\u306a\u304f\u898b\u3064\u304b\u308b\u3068\u3044\u3046\u5e0c\u671b\u3092\u4e0e\u3048\u307e\u3059\u3002\u79c1\u305f\u3061\u306f\u3064\u3044\u306b\u3001\u91cd\u5ea6\u8996\u529b\u55aa\u5931\u60a3\u8005\u306e\u305f\u3081\u306e\u3001\u5f71\u97ff\u529b\u306e\u3042\u308b\u5916\u6765\u8a3a\u7642\u3067\u5b9f\u65bd\u53ef\u80fd\u306a\u3001\u5909\u7570\u306b\u4f9d\u5b58\u3057\u306a\u3044\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u5b9f\u73fe\u306b\u8fd1\u3065\u3044\u3066\u3044\u307e\u3059\u3002\u300d RESTORE\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3044\u3066\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u8996\u529b\u6539\u5584\u3092\u793a\u3057\u305f\u53f2\u4e0a\u521d\u306eRCT\u3067\u3042\u308a\u3001Nanoscope\u793e\u306eRP\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u305f\u3081\u306b\u8a08\u753b\u3055\u308c\u3066\u3044\u308b\u4eca\u5f8c\u306eBLA\u7533\u8acb\u306e\u91cd\u8981\u306a\u90e8\u5206\u3067\u3059\u3002RESTORE\u7814\u7a76\u306e\u30c7\u30b6\u30a4\u30f3\u306f\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">\u4ee5\u524d\u306b\u767a\u8868\u3055\u308c\u305f<\/a>.\u300cNanoscope\u306f\u3001\u5149\u907a\u4f1d\u5b66\u5206\u91ce\u306e\u30ea\u30fc\u30c0\u30fc\u3067\u3042\u308b\u3053\u3068\u3092\u8a87\u308a\u306b\u601d\u3063\u3066\u3044\u307e\u3059\u3002\u5909\u7570\u3084\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u3001\u53ef\u8996\u5149\u30b9\u30da\u30af\u30c8\u30eb\u5168\u4f53\u304a\u3088\u3073\u5468\u56f2\u306e\u5149\u30ec\u30d9\u30eb\u306b\u304a\u3044\u3066\u3001\u8fc5\u901f\u306a\u53cd\u5fdc\u901f\u5ea6\u3068\u611f\u5ea6\u3067\u6700\u9069\u306a\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u3092\u767a\u63ee\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u305f\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u300d\u3068\u3001Nanoscope\u306e\u5171\u540c\u5275\u8a2d\u8005\u517c\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\u3067\u3042\u308b\u30b9\u30e9\u30ac\u30ca\u30fb\u30d0\u30c3\u30bf\u30c1\u30e3\u30ea\u30e4\u6c0f\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u79c1\u305f\u3061\u306f\u3001\u6e80\u305f\u3055\u308c\u3066\u3044\u306a\u3044\u30cb\u30fc\u30ba\u304c\u9ad8\u3044\u3053\u3068\u3092\u8a8d\u8b58\u3057\u3066\u304a\u308a\u3001\u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u6c38\u7d9a\u7684\u304b\u3064\u9032\u884c\u6027\u306e\u8996\u529b\u55aa\u5931\u3092\u62b1\u3048\u308b\u60a3\u8005\u3055\u3093\u306bMCO-010\u3092\u304a\u5c4a\u3051\u3059\u308b\u305f\u3081\u306b\u5c3d\u529b\u3057\u3066\u3044\u307e\u3059\u3002\u60a3\u8005\u3055\u3093\u3053\u305d\u304c\u79c1\u305f\u3061\u306e\u7f85\u91dd\u76e4\u3067\u3059\u3002\u300d\u201c\n\n<b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u3063\u3066\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306e\u4e3b\u8981\u8cc7\u7523\u3067\u3042\u308bMCO-010\u306f\u3001\u6700\u8fd1\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\u540c\u793e\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u305d\u3057\u3066\u6700\u8fd1\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-us-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration-302247017.html\" target=\"_blank\" rel=\"nofollow noopener\">\u7b2c3\u30d5\u30a7\u30fc\u30ba\u3092\u958b\u59cb\u3059\u308b\u8a08\u753b\u3092\u767a\u8868\u3057\u305f<\/a>\u00a02025\u5e74\u7b2c1\u56db\u534a\u671f\u306b\u767b\u9332\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u307e\u3059\u3002MCO-010\u306f\u3001RP\u3068Stargardt\u306e\u4e21\u65b9\u3067FDA\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068FDA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054MCO-020\u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002\n\n<b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a>\n\n<\/div>\n<\/div>\n<\/section><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS-Oct. 31, 2024 \u2014 Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that positive 2-year results from the Phase\u00a02b\u00a0RESTORE randomized, controlled clinical trial (RCT) of its lead program, MCO-010,\u00a0a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retinitis pigmentosa (RP) were presented by\u00a0Allen C. Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope, on\u00a0October 20, 2024 at the recently concluded\u00a0AAO 2024 Annual Meeting. During his presentation titled \u201cEfficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5852,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-31T21:10:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:07:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa\",\"datePublished\":\"2024-10-31T21:10:24+00:00\",\"dateModified\":\"2025-06-27T16:07:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/\"},\"wordCount\":627,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_AAO_Post_results.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_AAO_Post_results.jpg\",\"datePublished\":\"2024-10-31T21:10:24+00:00\",\"dateModified\":\"2025-06-27T16:07:05+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_AAO_Post_results.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_AAO_Post_results.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/31\\\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e2\u5e74\u9593\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-10-31T21:10:24+00:00","article_modified_time":"2025-06-27T16:07:05+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa","datePublished":"2024-10-31T21:10:24+00:00","dateModified":"2025-06-27T16:07:05+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/"},"wordCount":627,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e2\u5e74\u9593\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","datePublished":"2024-10-31T21:10:24+00:00","dateModified":"2025-06-27T16:07:05+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/31\/nanoscope-presented-positive-2-year-randomized-controlled-trial-results-of-mco-010-for-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5850"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5850\/revisions"}],"predecessor-version":[{"id":9030,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5850\/revisions\/9030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5852"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}